Ferrocifen type anti cancer drugs.

摘要: Despite current developments in therapeutics focusing on biotechnologically-oriented species, the unflagging utility of small molecules or peptides medicine is still producing strong results. In 2014 for example, 41 new medicines authorized sale, 33 belonged to category molecules, while 2013 they represented 24 27, according FDA. This can be explained as result recent forays into long-neglected areas chemistry. Medicinal organometallic chemistry provide us with an antimalarial against resistant parasitic strains, attested by phase II clinical development ferroquine, a framework conceptual advances based three-dimensional space-filling, and redox indeed catalytic intracellular properties. this context, bioferrocene species antiproliferative potential have several years been subject sustained effort, some initial successes nature ferrocene stable aromatic, low toxicity, cost, possessing reversible We show here different antitumoral approaches offered ferrocifen derivatives, originally simple derivatives tamoxifen, which over course their proved possess remarkable structural mechanistic diversity. These entities act via various targets, identified, that are triggered concentration products. They also cancer cells functionality, pathways operate either synergistically not, successive, concomitant sequential ways, depending example newly identified signaling inducing senescence apoptosis. Here we present first attempt rationalize behavior these anticancer targets.